A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.
Since the discovery of the biological effects of adenosine, the development of potent and selective agonists and antagonists of adenosine receptors has been the subject of medicinal chemistry research for several decades, even if their clinical evaluation has been discontinued. Main problems include side effects due to the ubiquity of the receptors and the possibility of side effects, or to low brain penetration (in particular for the targeting of CNS diseases), short half-life of compounds, lack of effects. Furthermore, species differences in the affinity of ligands make difficult preclinical testing in animal models. Nevertheless, adenosine receptors continue to represent promising drug targets. A(2A) receptor has proved to be a promising pharmacological target for small synthetic ligands, and while A(2A) agonists are undergoing clinical trials for myocardial perfusion imaging and as anti-inflammatory agents, A(2A) antagonists represent an attractive field of research to discover new drugs for the treatment of neurodegenerative disorders, such as Parkinson's disease. Furthermore, the information coming from bioinformatics and molecular modeling studies for the A(2A) receptor has made easier the understanding of ligand-target interaction and the rational design of agonists and antagonists for this subtype. The aim of this review is to show an overview of the most significant steps and progresses in developing A(2A) adenosine receptor agonists and antagonists.
Dipartimento di Scienze Chimiche, Università di Camerino, via S. Agostino 1, 62032 Camerino (MC), Italy. gloria.cristalli@unicam.it
G
G
Cristalli
C
C
Lambertucci
G
G
Marucci
R
R
Volpini
D
D
Dal Ben
D000225:Adenine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D058908:Adenosine A2 Receptor Agonists; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D015195:Drug Design; D054333:Drug Partial Agonism; D006801:Humans; D008024:Ligands; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology; D011487:Protein Conformation; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000378:metabolism; D043705:Receptor, Adenosine A2A / Q000737:chemistry; D013329:Structure-Activity Relationship; D014970:Xanthines / Q000737:chemistry / Q000494:pharmacology
D058908:Adenosine A2 Receptor Agonists; D058917:Adenosine A2 Receptor Antagonists; D008024:Ligands; D018696:Neuroprotective Agents; D019275:Radiopharmaceuticals; D043705:Receptor, Adenosine A2A; D014970:Xanthines; D000225:Adenine; D000241:Adenosine